These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 33613929)

  • 1. Interferon-α may help prevent molecular relapse of chronic myeloid leukemia after the discontinuation of tyrosine kinase inhibitors.
    Jun K; Ya-Zhen Q; Xiao-Su Z; Hong-Xia S; Yue-Yun L; Kai-Yan L; Xiao-Jun H; Hao J
    Ther Adv Hematol; 2021; 12():2040620720986643. PubMed ID: 33613929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Observational study of chronic myeloid leukemia Chinese patients who discontinued tyrosine kinase inhibitors in the real-world].
    Zhao HF; Yang YF; Liu BC; Li WM; Xu N; Liu XL; Jiang Q; Dang HB; Liang LX; Zhang Y; Song YP
    Zhonghua Xue Ye Xue Za Zhi; 2022 Aug; 43(8):636-643. PubMed ID: 36709147
    [No Abstract]   [Full Text] [Related]  

  • 3. Profiles of NK cell subsets are associated with successful tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia and changes following interferon treatment.
    Kong J; Qin YZ; Zhao XS; Hou Y; Liu KY; Huang XJ; Jiang H
    Ann Hematol; 2021 Oct; 100(10):2557-2566. PubMed ID: 34278524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study.
    Cayssials E; Torregrosa-Diaz J; Gallego-Hernanz P; Tartarin F; Systchenko T; Maillard N; Desmier D; Machet A; Fleck E; Corby A; Motard C; Denis G; Herbelin A; Gombert JM; Roy L; Ragot S; Leleu X; Guilhot F; Chomel JC
    Cancer; 2020 Aug; 126(15):3438-3447. PubMed ID: 32459375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discontinuation of tyrosine kinase inhibitors in pediatric chronic myeloid leukemia.
    Shima H; Kada A; Tanizawa A; Sato I; Tono C; Ito M; Yuza Y; Watanabe A; Kamibeppu K; Uryu H; Koh K; Imai C; Yoshida N; Koga Y; Fujita N; Saito AM; Adachi S; Ishii E; Shimada H
    Pediatr Blood Cancer; 2022 Aug; 69(8):e29699. PubMed ID: 35403816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors.
    Haddad FG; Sasaki K; Issa GC; Garcia-Manero G; Ravandi F; Kadia T; Cortes J; Konopleva M; Pemmaraju N; Alvarado Y; Yilmaz M; Borthakur G; DiNardo C; Jain N; Daver N; Short NJ; Jabbour E; Kantarjian H
    Am J Hematol; 2022 Jul; 97(7):856-864. PubMed ID: 35357036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of unplanned tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: retrospective analysis of real-world experience in a single institution.
    Iino M; Yamamoto T; Sakamoto Y
    Hematology; 2019 Dec; 24(1):355-361. PubMed ID: 30880635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discontinuation of Tyrosine Kinase Inhibitor Therapy and Treatment Free Remission (TFR) in Chronic Myeloid Leukemia: Successful Achievement of TFR in More Than Two-Third of Patients in a Real-World Practice.
    Aleem A; Shaheen NA; Algahtani F; Jamal A; Alkhudair N; Alghafis M; Iqbal Z; Siti HWZ; Thomas A; Alahmari B; Salama H; Gmati G; Alzahrani M; Alhejazi A; Alfayez M; Alrajhi A; Marei MA; Alaskar A
    Clin Lymphoma Myeloma Leuk; 2024 Aug; ():. PubMed ID: 39299826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Planned Pregnancy in Female Patients with Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitor Therapy.
    Dou X; Qin Y; Huang X; Jiang Q
    Oncologist; 2019 Nov; 24(11):e1141-e1147. PubMed ID: 31186377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.
    Saussele S; Richter J; Guilhot J; Gruber FX; Hjorth-Hansen H; Almeida A; Janssen JJWM; Mayer J; Koskenvesa P; Panayiotidis P; Olsson-Strömberg U; Martinez-Lopez J; Rousselot P; Vestergaard H; Ehrencrona H; Kairisto V; Machová Poláková K; Müller MC; Mustjoki S; Berger MG; Fabarius A; Hofmann WK; Hochhaus A; Pfirrmann M; Mahon FX;
    Lancet Oncol; 2018 Jun; 19(6):747-757. PubMed ID: 29735299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Tyrosine kinase inhibitors discontinuation for chronic myeloid leukemia: a multicenter retrospective analysis in China].
    Zhu XJ; You Y; Duan MH; Zhu Y; Liu BC; Chen SN; Du X
    Zhonghua Xue Ye Xue Za Zhi; 2018 Dec; 39(12):994-997. PubMed ID: 30612400
    [No Abstract]   [Full Text] [Related]  

  • 12. [Analysis the influence factors of treatment free remission outcome with chronic myeloid leukemia patients who discontinued tyrosine kinase inhibitors].
    Zhao HF; Zhang Y; Dang LX; Liang JL; Chen SX; Guo Z; Li YL; Zu RR; Gui XD; Wei YP; Song Y
    Zhonghua Yi Xue Za Zhi; 2022 May; 102(20):1523-1529. PubMed ID: 35692068
    [No Abstract]   [Full Text] [Related]  

  • 13. [Analysis on tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia in the real world: experience from single center].
    Yu L; Qin YZ; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2017 Sep; 38(9):754-760. PubMed ID: 29081191
    [No Abstract]   [Full Text] [Related]  

  • 14. [A Retrospective Analysis of TKI Discontinuation in Patients with CML].
    Zhao XL; Hong M; Qiao C; Sun Q; Zhu H; Wang S; Li JY; Qian SX; Zhu Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Dec; 29(6):1746-1751. PubMed ID: 34893104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imatinib and pegylated IFN-α2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response.
    Koskenvesa P; Kreutzman A; Rohon P; Pihlman M; Vakkila E; Räsänen A; Vapaatalo M; Remes K; Lundán T; Hjorth-Hansen H; Vakkila J; Simonsson B; Mustjoki S; Porkka K
    Eur J Haematol; 2014; 92(5):413-20. PubMed ID: 24372965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Results of following up patients with chronic myeloid leukemia and a deep molecular response without tyrosine kinase inhibitor therapy].
    Turkina AG; Chelysheva EY; Shuvaev VA; Gusarova GA; Bykova AV; Shukhov OA; Petrova AN; Vakhrusheva MV; Goryacheva SR; Kolosova LY; Krasikova PS; Fominykh MS; Martynkevich IS; Abdullaev AO; Sudarikov AB; Savchenko VG
    Ter Arkh; 2017; 89(12):86-96. PubMed ID: 29411766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetics of
    Murbach B; Duarte G; Palma LC; Miranda E; Duffles G; Furlin GP; Toni I; De Souza C; Binelli L; Bassan VL; de Castro FA; de Figueiredo-Pontes LL; Pagnano KBB
    Front Oncol; 2024; 14():1393191. PubMed ID: 38779092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation.
    Bernardi S; Malagola M; Zanaglio C; Polverelli N; Dereli Eke E; D'Adda M; Farina M; Bucelli C; Scaffidi L; Toffoletti E; Deambrogi C; Stagno F; Bergamaschi M; Franceschini L; Abruzzese E; Divona MD; Gobbi M; Di Raimondo F; Gaidano G; Tiribelli M; Bonifacio M; Cattaneo C; Iurlo A; Russo D
    Cancer Med; 2019 May; 8(5):2041-2055. PubMed ID: 30950237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, phase II trial of adjuvant immunotherapy with durable TKI-free survival in patients with chronic phase CML.
    Webster JA; Robinson TM; Blackford AL; Warlick E; Ferguson A; Borrello I; Zahurak M; Jones RJ; Smith BD
    Leuk Res; 2021 Dec; 111():106737. PubMed ID: 34768161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring Treatment-Free Remission by Droplet Digital PCR in CML Patients with Deep Molecular Response to Tyrosine Kinase Inhibitor: An Analysis Based on Real-World Data.
    Zhu G; Yang Y; Wang H; Xie J; Hu J; Guo W; Zhang L; Liu Z; Chen X; Chang J; Xu J; Tan Y
    Ann Clin Lab Sci; 2020 Sep; 50(5):591-599. PubMed ID: 33067205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.